284 related articles for article (PubMed ID: 10825037)
61. [Acute meningococcal disease. Its prognostic assessment].
Bermúdez de la Vega JA; Gómez Calzado A; Sobrino Toro M; Alejo Garcia-Mauricio A; Romero Cachaza J; González Hachero J
An Esp Pediatr; 1993 Sep; 39(3):214-8. PubMed ID: 8250434
[TBL] [Abstract][Full Text] [Related]
62. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
[TBL] [Abstract][Full Text] [Related]
63. Analgesia-sedation in PICU and neurological outcome: a secondary analysis of long-term neuropsychological follow-up in meningococcal septic shock survivors*.
van Zellem L; Utens EM; de Wildt SN; Vet NJ; Tibboel D; Buysse C
Pediatr Crit Care Med; 2014 Mar; 15(3):189-96. PubMed ID: 24366510
[TBL] [Abstract][Full Text] [Related]
64. [A case of meningococcal sepsis].
Bonzano L; Colombino G; Petri G; Vittone L; Barbera C; Manzoni R
Minerva Med; 1990 Mar; 81(3 Suppl):49-51. PubMed ID: 2109279
[TBL] [Abstract][Full Text] [Related]
65. Antiendotoxin therapies for septic shock.
Corriveau CC; Danner RL
Infect Agents Dis; 1993 Feb; 2(1):44-52. PubMed ID: 8162353
[TBL] [Abstract][Full Text] [Related]
66. Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits.
Roback MG; Stack AM; Thompson C; Brugnara C; Schwarz HP; Saladino RA
Shock; 1998 Feb; 9(2):138-42. PubMed ID: 9488260
[TBL] [Abstract][Full Text] [Related]
67. Protein C concentrate and recombinant tissue plasminogen activator in meningococcal septic shock.
Leclerc F; Cremer R; Leteurtre S; Martinot A; Fourier C
Crit Care Med; 2000 May; 28(5):1694-7. PubMed ID: 10834762
[No Abstract] [Full Text] [Related]
68. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
Quintiliani R; Cooper B; Maderazo E; Nightingale C
Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
[TBL] [Abstract][Full Text] [Related]
69. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].
van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630
[No Abstract] [Full Text] [Related]
70. Comparison of HA-1A and E5 monoclonal antibodies to endotoxin in rats with endotoxaemia.
Boom SJ; Davidson JA; Zhang P; Reidy J; Ramsay G
Eur J Surg; 1993 Oct; 159(10):559-61. PubMed ID: 8286515
[TBL] [Abstract][Full Text] [Related]
71. Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy.
Brandtzaeg P; Bryn K; Kierulf P; Ovstebø R; Namork E; Aase B; Jantzen E
J Clin Invest; 1992 Mar; 89(3):816-23. PubMed ID: 1541674
[TBL] [Abstract][Full Text] [Related]
72. [Hemodynamic study in meningococcal septic shock].
Mar Molinero F; Flores Antón B; Espino Hernández M; Medina Monzón C; Garrido Borreguero E; Sánchez Díaz I; Melian Machin A
An Esp Pediatr; 1991 Jul; 35(1):21-5. PubMed ID: 1772167
[TBL] [Abstract][Full Text] [Related]
73. Elevated VIP and endotoxin plasma levels in human gram-negative septic shock.
Brandtzaeg P; Oktedalen O; Kierulf P; Opstad PK
Regul Pept; 1989 Jan; 24(1):37-44. PubMed ID: 2500680
[TBL] [Abstract][Full Text] [Related]
74. The economic impact of HA-1A (Centoxin) against endotoxin.
Barriere SL
Pharmacoeconomics; 1992 Nov; 2(5):408-13. PubMed ID: 10147053
[TBL] [Abstract][Full Text] [Related]
75. [Studying the levels of endotoxemia in meningococcal sepsis. Its relations to pregnancy and antibiotic treatment].
Loscertales Abril M; Ruiz Extremera A; Rodríguez Contreras R; Galvez Vargas R; Gómez Vida J; Ibarra de la Rosa I; del Castillo Aguas G; Molina Font JA
An Esp Pediatr; 1991 May; 34(5):355-9. PubMed ID: 1883109
[TBL] [Abstract][Full Text] [Related]
76. [Preventive interruption of the administration of HA-1A monoclonal antibody against endotoxin].
Torrabadella de Reynoso P; Trilla A; Salgado A; Ribas J
Med Clin (Barc); 1993 Apr; 100(13):518. PubMed ID: 8479241
[No Abstract] [Full Text] [Related]
77. Heparin for infants and children with meningococcal septicemia. Results of a randomized therapeutic trial.
Haneberg B; Gutteberg TJ; Moe PJ; Osterud B; Bjorvatn B; Lehmann EH
NIPH Ann; 1983 Jun; 6(1):43-7. PubMed ID: 6353278
[TBL] [Abstract][Full Text] [Related]
78. [Meningitis and septic shock as acute, fatal conditions].
Brandtzaeg P
Tidsskr Nor Laegeforen; 1993 Jun; 113(16):1994-7. PubMed ID: 8322350
[TBL] [Abstract][Full Text] [Related]
79. Massive Organ Inflammation in Experimental and in Clinical Meningococcal Septic Shock.
Hellerud BC; Olstad OK; Nielsen EW; Trøseid AM; Skadberg Ø; Thorgersen EB; Vege Å; Mollnes TE; Brandtzæg P
Shock; 2015 Nov; 44(5):458-69. PubMed ID: 26473439
[TBL] [Abstract][Full Text] [Related]
80. [Value of heparin in the treatment of meningococcal purpura fulminans. 3 cases].
Charlas J; Thieffry JC; Madelin JC; Dardenne P; Meyer B; Paupe J; Vialatte J
Ann Pediatr (Paris); 1970; 17(8):553-9. PubMed ID: 5455263
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
